Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KURA Kura Oncology

Not Yet Opened 12-22 16:00:00 EST

11.27

+1.43

+14.53%

盘后11.27

+0.000.00%

19:40 EST

High11.28	Low10.33	Vol2.01M
Open10.35	D1 Closing9.84	Amplitude9.65%
Mkt Cap980.69M	Tradable Cap721.12M	Total Shares87.02M
T/O22.19M	T/O Rate3.15%	Tradable Shares63.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KURA","market":"US","secType":"STK","nameCN":"Kura Oncology","latestPrice":11.27,"timestamp":1766437200000,"preClose":9.84,"halted":0,"volume":2012987,"hourTrading":{"tag":"盘后","latestPrice":11.27,"preClose":11.27,"latestTime":"19:40 EST","volume":183665,"amount":2070152.517,"timestamp":1766450402063},"delay":0,"floatShares":63985582,"shares":87017518,"eps":-2.480148,"marketStatus":"Not Yet Opened","change":1.43,"latestTime":"12-22 16:00:00 EST","open":10.35,"high":11.28,"low":10.33,"amount":22192644.207471,"amplitude":0.096545,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.480148,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1446699600000,"exchange":"NASDAQ","adjPreClose":9.84,"preHourTrading":{"tag":"盘前","latestPrice":10.51,"preClose":9.84,"latestTime":"09:27 EST","volume":24091,"amount":252127.130965,"timestamp":1766413648306},"postHourTrading":{"tag":"盘后","latestPrice":11.27,"preClose":11.27,"latestTime":"19:40 EST","volume":183665,"amount":2070152.517,"timestamp":1766450402063},"volumeRatio":0.770168,"impliedVol":0.609,"impliedVolPercentile":0.3213},"requestUrl":"/m/hq/s/KURA","defaultTab":"news","newsList":[{"id":"2592190378","title":"Kura Oncology Chief Scientific Officer Francis Burrows Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592190378","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592190378?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:30","pubTimestamp":1766179833,"startTime":"0","endTime":"0","summary":"Francis Burrows, Chief Scientific Officer of Kura Oncology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL64V6N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kura Oncology Chief Scientific Officer Francis Burrows Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KURA","BK4139"],"gpt_icon":0},{"id":"2590558168","title":"Kura Oncology Director Faheem Hasnain Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558168","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558168?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400739,"startTime":"0","endTime":"0","summary":"Faheem Hasnain, Director at Kura Oncology Inc., has reported a disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL4w2j1z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kura Oncology Director Faheem Hasnain Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4505","BK4139"],"gpt_icon":0},{"id":"2589544543","title":"Kura Oncology Inc - Registrational Trials of Ziftomenib in Front-Line Aml Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589544543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589544543?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:40","pubTimestamp":1765208405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"2589354451","title":"Kura Oncology Inc - Triplet Combination for Komzifti With Venetoclax and Azacitidine  Well Tolerated in Newly Diagnosed and R/R Settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589354451?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:40","pubTimestamp":1765208405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","KURA","BK4139"],"gpt_icon":0},{"id":"2589735464","title":"Kura Oncology Reports Positive Data for KOMZIFTI Triplet Combo in AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589735464","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589735464?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:30","pubTimestamp":1765207814,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL8tr06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU2210149790.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","BK4585","BK4139","IE00B64PRP62.GBP","SG9999014039.USD","BK4112","BK4505","SG9999014013.SGD","KURA","LU2210150020.SGD"],"gpt_icon":0},{"id":"2589435418","title":"Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2589435418","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589435418?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:30","pubTimestamp":1765207800,"startTime":"0","endTime":"0","summary":"– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and over","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201703/35186/en/Kura-Oncology-and-Kyowa-Kirin-Report-Combination-Data-for-KOMZIFTI-Ziftomenib-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-and-Relapsed-Refractory-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGS","KURA","BK4505","BK4179","BK4139"],"gpt_icon":0},{"id":"2588418270","title":"Kura Oncology Hosts Virtual Investor Event on Ziftomenib Triplet Data in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2588418270","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588418270?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:32","pubTimestamp":1764768730,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL8pxhl1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4505","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","NDAQ","KURA","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2588053285","title":"Kura Oncology Secures $135 Million Milestone Payment from Kyowa Kirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053285","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053285?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680568,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc. announced the completion of the first U.S. commercial sale of KOMZIFTI , following its FDA approval on November 13, 2025. This sale has triggered a $135 million milestone payment to Kura under its collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. Kura expects to receive the payment before the end of the year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL5sknTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","BK4505","LU2210149790.SGD","BK4588","KURA","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588905349","title":"First U.S. Commercial Sale of Komzifti™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement With Kyowa Kirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2588905349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588905349?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680520,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA86G3JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"2586289851","title":"Positive Outlook on Kura Oncology: Komzii’s Approval and Safety Profile Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2586289851","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586289851?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:45","pubTimestamp":1764121527,"startTime":"0","endTime":"0","summary":"Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Kura Oncology and keeping the price target at $28.00. Charles Zhu has given his...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-kura-oncology-komziis-approval-and-safety-profile-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-kura-oncology-komziis-approval-and-safety-profile-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA"],"gpt_icon":0},{"id":"2586240498","title":"FDA Approves Kura Oncology’s KOMZIFTI for Relapsed or Refractory NPM1-Mutated AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2586240498","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586240498?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:17","pubTimestamp":1764109030,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc. has received full approval from the U.S. Food and Drug Administration for KOMZIFTI , an oral menin inhibitor, for the treatment of adults with relapsed or refractory acute myeloid leukemia  with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. This approval was supported by data from the KOMET-001 clinical trial and marks KOMZIFTI as the first and only once-daily FDA-approved menin inhibitor for this indication. The therapy has also been added to the National Comprehensive Cancer Network  Clinical Practice Guidelines in Oncology as a Category 2A recommended treatment option.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to gene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL1VClv1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4505","BK4139","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4588","LU2210150020.SGD","KURA","LU2095319765.USD","LU0314104364.USD","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2585498081","title":"Kura Oncology Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498081","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585498081?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:42","pubTimestamp":1763995320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 09:42 ET (14:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA"],"gpt_icon":0},{"id":"2585573794","title":"Barclays Remains a Buy on Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585573794","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585573794?lang=en_us&edition=fundamental","pubTime":"2025-11-24 16:45","pubTimestamp":1763973939,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Buy rating on Kura Oncology today and set a price target of $28.00. According to TipRanks, Darout is a 5...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-kura-oncology-kura-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-kura-oncology-kura-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"2584392559","title":"Kura Oncology Receives Second $30 Million Development Milestone Payment In Aml Menin Inhibitor Program With Kyowa Kirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2584392559","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584392559?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:27","pubTimestamp":1763569659,"startTime":"0","endTime":"0","summary":"Nov 4 (Reuters) - Kura Oncology Inc ::*KURA ONCOLOGY RECEIVES SECOND $30 MILLION DEVELOPMENT MILESTONE PAYMENT IN AML MENIN INHIBITOR PROGRAM WITH KYOWA KIRIN*KURA ONCOLOGY INC - EXPECTS UP TO $315 MI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDb0bXp4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4505","BK4139"],"gpt_icon":0},{"id":"2583282633","title":"Kura Oncology SVP Finance Thomas Doyle Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583282633","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583282633?lang=en_us&edition=fundamental","pubTime":"2025-11-15 09:00","pubTimestamp":1763168445,"startTime":"0","endTime":"0","summary":"Thomas James Doyle, Senior Vice President of Finance & Accounting at Kura Oncology Inc., reported a disposal of common shares of Kura Oncology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251115:nNDL9zSJdQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kura Oncology SVP Finance Thomas Doyle Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"2583685995","title":"Kura Scores A Big Win As FDA Approves Its New Leukemia Pill","url":"https://stock-news.laohu8.com/highlight/detail?id=2583685995","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583685995?lang=en_us&edition=fundamental","pubTime":"2025-11-15 01:43","pubTimestamp":1763142180,"startTime":"0","endTime":"0","summary":"Komzifti wins full FDA approval for NPM1-mutated AML, supported by KOMET-001 data, as Wedbush boosts Kura Oncology's price target to $38.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/14/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/14/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/11/48873174/kura-scores-a-big-win-as-fda-approves-its-new-leukemia-pill","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/11/48873174/kura-scores-a-big-win-as-fda-approves-its-new-leukemia-pill","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["CR","BK4505","BK4139","BK4161","KURA"],"gpt_icon":0},{"id":"2583468892","title":"Kura Oncology Up Over 16%, On Pace for Largest Percent Increase Since January 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2583468892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583468892?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:28","pubTimestamp":1763137680,"startTime":"0","endTime":"0","summary":"Kura Oncology, Inc.  is currently at $12.44, up $1.76 or 16.48%. --Would be highest close since Nov. 20, 2024, when it closed at $15.91. --On pace for largest percent increase since Jan. 24, 2024, when it rose 46.13%. --Up 26.17% this week; best weekly performance since the week ending Aug. 15, 2025, when it rose 32.49%. --Up 42.82% year-to-date; on pace for best year since 2020, when it rose 137.53%. --Down 70.11% from its all-time closing high of $41.62 on Dec. 11, 2020. --Down 21.86% from 52 weeks ago , when it closed at $15.92. --Down 22.44% from its 52-week closing high of $16.04 on Nov. 18, 2024. --Traded as high as $12.47; highest intraday level since Nov. 20, 2024, when it hit $16.09","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KURA","BK4505"],"gpt_icon":0},{"id":"2583070345","title":"Kura Oncology Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2583070345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583070345?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:26","pubTimestamp":1763133960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 10:26 ET (15:26 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA"],"gpt_icon":0},{"id":"2583507275","title":"Kura Oncology Inc : UBS Raises Target Price to $16 From $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2583507275","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583507275?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:21","pubTimestamp":1763133714,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nAZN4QS4G5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","KURA","BK4139"],"gpt_icon":0},{"id":"2583502606","title":"Kura Oncology price target raised to $30 from $29 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502606","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583502606?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:35","pubTimestamp":1763130939,"startTime":"0","endTime":"0","summary":"BofA analyst Jason Zemansky raised the firm’s price target on Kura Oncology (KURA) to $30 from $29 and keeps a Buy rating on the shares. The FDA ap...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kura-oncology-price-target-raised-to-30-from-29-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kura-oncology-price-target-raised-to-30-from-29-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kuraoncology.com","stockEarnings":[{"period":"1week","weight":0.0672},{"period":"1month","weight":0.009},{"period":"3month","weight":0.3677},{"period":"6month","weight":0.9431},{"period":"1year","weight":0.2508},{"period":"ytd","weight":0.2939}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.024387},{"month":2,"riseRate":0.5,"avgChangeRate":0.027496},{"month":3,"riseRate":0.6,"avgChangeRate":-0.029894},{"month":4,"riseRate":0.2,"avgChangeRate":-0.031764},{"month":5,"riseRate":0.5,"avgChangeRate":0.015121},{"month":6,"riseRate":0.5,"avgChangeRate":0.037607},{"month":7,"riseRate":0.5,"avgChangeRate":0.037366},{"month":8,"riseRate":0.5,"avgChangeRate":0.066679},{"month":9,"riseRate":0.5,"avgChangeRate":0.12103},{"month":10,"riseRate":0.3,"avgChangeRate":-0.077132},{"month":11,"riseRate":0.8,"avgChangeRate":0.052179},{"month":12,"riseRate":0.454545,"avgChangeRate":0.010259}],"exchange":"NASDAQ","name":"Kura Oncology","nameEN":"Kura Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kura Oncology(KURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kura Oncology,KURA,Kura Oncology股票,Kura Oncology股票老虎,Kura Oncology股票老虎国际,Kura Oncology行情,Kura Oncology股票行情,Kura Oncology股价,Kura Oncology股市,Kura Oncology股票价格,Kura Oncology股票交易,Kura Oncology股票购买,Kura Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kura Oncology(KURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction